First-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib have significant activity in NSCLC patients with activating EGFR mutations. However, EGFR-TKI resistance inevitably occurs after approximately 12 months of treatment. Acquired mechanisms of resistance, other than secondary mutations in EGFR (T790 M) which account for 50-60%, are less well understood.
View Article and Find Full Text PDFZhonghua Yi Xue Za Zhi
August 2012
Objective: To examine whether the isoflurane-induced spatial memory changes is associated with AD pathogenesis of tau protein phosphorylation.
Methods: We exposed 18-month-old male Sprague-Dawley rats to 1.4% isoflurane for 2 hours (anesthesia group, n = 31).